Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 11/20 | 0.49 |
| ▸ | SPHK1 | Q9NYA1 | 11/20 | 0.49 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5488381 | 1.00 | SPHK2 (0.49) | SPHK2SPHK1CCNE2CDK4CCND1 | |
| SCHEMBL5486137 | 0.88 | SPHK2 (0.53) | SPHK2SPHK1CCNE2CDK4CCND1 | |
| SCHEMBL5486142 | 0.88 | SPHK2 (0.53) | SPHK2SPHK1CCNE2CDK4CCND1 | |
| SCHEMBL5486187 | 0.85 | CCNE2 (0.44) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL5486197 | 0.85 | CCNE2 (0.44) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL5486454 | 0.85 | SPHK2 (0.41) | SPHK2SPHK1CCNE2CDK4CCND1 | |
| SCHEMBL5486462 | 0.85 | SPHK2 (0.41) | SPHK2SPHK1CCNE2CDK4CCND1 | |
| SCHEMBL5033251 | 0.85 | SPHK2 (0.49) | SPHK2SPHK1ACVR1 | |
| SCHEMBL5033262 | 0.85 | SPHK2 (0.49) | SPHK2SPHK1ACVR1 | |
| SCHEMBL5486309 | 0.84 | CCNE2 (0.41) | SPHK2SPHK1CCNE2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205309-B2 | Quinazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1560816-A1 | QUINAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-10 | — | — | EP | disclosed |
| US-20040029901-A1 | Quinazoline derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-12 | — | — | US | disclosed |
| WO-2004005265-A1 | QUINAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029901-A1 | Quinazoline derivatives | GPR119, NQO2, CYP7A1 | SPHK2 2812/4885SPHK1 2519/4885CCNE2 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.